Aim Approximately 20% of patients treated with neoadjuvant chemoradiotherapy (nCRT) for
locally advanced rectal cancer achieve a pathological complete response (p CR) while the …

The monolithic approach to apply the same schedule of preoperative 5-fluorouracil (5-FU)-or
capecitabine-based chemoradiotherapy (CRT) to all patients with clinically staged TNM …

KRAS-activating mutations are oncogenic drivers and are correlated with radioresistance of
multiple cancers, including colorectal cancer, but the underlying precise molecular …

Introduction: Patients with locally advanced rectal cancer (LARC) are undergoing
neoadjuvant chemoradiotherapy (NCRT) prior to surgery. Although in some patients the …

Colorectal cancer (CRC) is a heterogeneous disease with genetic profiles and clinical
outcomes dependent on the anatomic location of the primary tumor. How location has an …

INTRODUCTION: The current management of locally advanced rectal cancer involves total
mesorectal excision, which may be preceded by neo-adjuvant chemoradiotherapy (CRT) …

At this time, the use of oxaliplatin or targeted agents as component of multimodality
treatment for rectal cancer outside of a clinical trial is not recommended. The inclusion of …

Rectal cancer accounts for a relevant part of colorectal cancer cases, with a mortality of 4-
10/100000 per year. The development of locoregional recurrences and the occurrence of …

Purpose Preoperative chemoradiation (CRT) for locally advanced rectal adenocarcinoma
achieves pathologic complete response (pCR) in 8–20% of patients. Mutations in critical …

Colorectal cancer (CRC) represents a major public health problem as the second leading
cause of cancer‐related mortality in the United States. Of an estimated 140,000 newly …